(2,3-difluorophenyl)methanesulfonyl Chloride | 886498-49-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,3-difluorophenyl)methanesulfonyl Chloride
• CAS: 886498-49-3
• 化学式: C₇H₅ClF₂O₂S
• 分子量: 226.63
• InChiKey: IVOZQYVSUGBOER-UHFFFAOYSA-N

物化性质

• 沸点：
  287.9±30.0 °C(Predicted)
• 密度：
  1.546±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] IRE1α MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE IRE1α ET LEURS UTILISATIONS
  申请人：NIMBUS IASO INC

  公开号：WO2021158516A1

  公开（公告）日：2021-08-12

  The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of IRE1α, and the treatment of IRE1α-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物调节IRE1α并治疗IRE1α介导的疾病的方法。
• Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders
  申请人：Genentech, Inc.

  公开号：US10968203B2

  公开（公告）日：2021-04-06

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  这里描述的是具有式 I 或 I′结构的嘧啶基吡啶氧基萘化合物，它们具有调节肌醇需要酶 1（IRE1）的活性或功能： 或其立体异构体、同系物或药学上可接受的盐，并具有本文所述的取代基和结构特征。还描述了包括式Ⅰ或Ⅰ′化合物的药物组合物和药物，以及单独或与其它治疗剂联合使用这种IRE1调节剂治疗由雌激素受体介导或依赖于雌激素受体的疾病或病症的方法。
• PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS
  申请人：Genentech, Inc.

  公开号：US20180265497A1

  公开（公告）日：2018-09-20

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.